EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

S100 as marker for immune effector cell-associated neurotoxicity syndrome

Axel Schulenburg, Lina Z Rüsing, Armin Bumberger, Margit Mitterbauer, Werner Rabitsch

Wiener klinische Wochenschrift · 2025

DOI: 10.1007/s00508-024-02451-0 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Wiener klinische Wochenschrift, 2025. Verfasst von Axel Schulenburg und 4 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplantation Unit, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria. axel.schulenburg@meduniwien.ac.at. Hauptthemen laut MEDLINE: Cytokine Release Syndrome, Immunotherapy, Adoptive, Neurotoxicity Syndromes, S100 Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR)-T cell therapy is a new and successful treatment for otherwise refractory malignancies but despite the growing number of applications, this form of treatment is still associated with significant toxicity. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in particular are common and dangerous side effects. This report is about two patients who received CAR‑T cell therapy and subsequently developed ICANS. This was successfully treated. During CAR‑T cell therapy, a blood marker, S100, was monitored daily. It correlated with the occurrence and progression of ICANS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytokine Release SyndromeImmunotherapy, AdoptiveNeurotoxicity SyndromesS100 ProteinsHumansMaleBiomarkersReceptors, Chimeric AntigenAged

Stichwörter der Autor:innen

Chimeric antigen receptor (CAR)-T cell therapyMarkerNeurologySide effectsToxicity

Substanzen

Biomarkerscell-associated neurotoxicityReceptors, Chimeric AntigenS100 Proteins

Autor:innen und Institutionen

  • Bone Marrow Transplantation Unit, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria. axel.schulenburg@meduniwien.ac.at.
  • Department of Medicine I, Stem Cell Transplantation Unit, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. axel.schulenburg@meduniwien.ac.at.
  • Bone Marrow Transplantation Unit, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.

Förderung

  • Medical University of Vienna

Zitieren

APA

Schulenburg, A., Rüsing, L. Z., Bumberger, A., Mitterbauer, M., & Rabitsch, W. (2025). S100 as marker for immune effector cell-associated neurotoxicity syndrome. Wiener klinische Wochenschrift. https://doi.org/10.1007/s00508-024-02451-0

Vancouver

Schulenburg A, Rüsing LZ, Bumberger A, Mitterbauer M, Rabitsch W. S100 as marker for immune effector cell-associated neurotoxicity syndrome. Wiener klinische Wochenschrift. 2025. doi:10.1007/s00508-024-02451-0

BibTeX
@article{Schulenburg2025,
  author = {Schulenburg, Axel and Rüsing, Lina Z and Bumberger, Armin and Mitterbauer, Margit and Rabitsch, Werner},
  title = {S100 as marker for immune effector cell-associated neurotoxicity syndrome},
  journal = {Wiener klinische Wochenschrift},
  year = {2025},
  doi = {10.1007/s00508-024-02451-0}
}
Kostenlos starten →